 ROCKAWAY, NJ, June 09, 2021 GLOBE NEWSWIRE -- electroCore, Inc. Nasdaq: ECOR, a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of 1.4 million of its available tax benefits through the New Jersey Economic Development Authoritys Technology Business Tax Certificate Transfer program for fiscal years 2019 and 2020. As a result, the Company has received approximately 1.4 million in non-dilutive cash from the sale of these net operating loss NOL tax benefits. 